Physician profile
Long Vu
NPI 1477973535
$4,374.98
in general payments reported to CMS, 2019-2025
27 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.59 · 2021: $232 · 2022: $194 · 2023: $1,027 · 2024: $1,097 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.43 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.13 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Genzyme Corporation | $478.50 | 2023-2025 | |
| Ardelyx, INC. | $405.84 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $382.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $335.56 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $301.95 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $232.11 | 2023-2025 | Tremfya, Simponi, Stelara |
| Qol Medical, LLC | $200.56 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.15 | 2019-2023 | Xifaxan, Trulance |
| Amgen INC. | $164.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.99 | 2023-2024 | Dupixent |
| Mml US, INC. | $119.23 | 2025 | Reactiv8 |
| E.R. Squibb & Sons, L.L.C. | $111.56 | 2021 | |
| Novo Nordisk INC | $81.73 | 2025 | Wegovy |
| Vivus LLC | $61.55 | 2024-2025 | Pancreaze |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $59.12 | 2023 | Sutab, Suflave |
| Celgene Corporation | $54.02 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $50.38 | 2024-2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $45.12 | 2025 | |
| Lilly USA, LLC | $39.73 | 2023-2024 | Omvoh |
| Gilead Sciences, INC. | $38.54 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $37.21 | 2024-2025 | Rebyota |
| Daiichi Sankyo INC. | $29.74 | 2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $21.53 | 2025 | Iqirvo |
| Medtronic, INC. | $18.87 | 2024 | Nexpowder |
| Pfizer INC. | $13.54 | 2025 | |
| Nestle Healthcare Nutrition INC. | $13.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.